Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma

Katsunori Tatsugami, Masatoshi Eto, Masahiko Harano, Masumitsu Hamaguchi, Toshihiro Miyamoto, Takashi Morisaki, Masutaka Furue, Koichi Akashi, Seiji Naito

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: To evaluate the safety and efficacy of dendritic cell (DC) therapy in combination with interferon-α (IFN-α) in patients with advanced renal cell carcinoma. Methods: Seven patients, with progressive disease following IFN-α and interleukin (IL)-2 treatment, were treated with monocyte-derived DC (Mo-DC) and IFN-α between February 2004 and September 2006. They received Mo-DC once a week for 5 weeks and then every 2 weeks either intradermally or intratumorally. IFN-α (5-6 million U) was subcutaneously administered three times a week. Tumor size was evaluated by computed tomography scans before and after the 5th and 10th DC vaccination. A delayed-type hypersensitivity test was performed after the 4th and 5th DC administration for immunological monitoring. Results: Five patients had stable disease while the remaining two patients had progressive disease following 4 months of vaccination. In six patients the time to progression was prolonged in comparison with the previous cytokine treatment. Six patients showed delayed-type hypersensitivity after the 4th or 5th immunization. Three patients developed high fever following DC immunization. Treatment was associated with transient flu-like symptoms. Conclusions: Our data indicate that DC therapy combined with IFN-α is safe and has the potential for prolonging the time to progression in patients with advanced renal cell carcinoma.

Original languageEnglish
Pages (from-to)694-698
Number of pages5
JournalInternational Journal of Urology
Volume15
Issue number8
DOIs
Publication statusPublished - Aug 1 2008

Fingerprint

Cell- and Tissue-Based Therapy
Renal Cell Carcinoma
Dendritic Cells
Interferons
Delayed Hypersensitivity
Therapeutics
Monocytes
Immunization
Vaccination
Immunologic Monitoring
Interleukin-2
Fever
Tomography
Cytokines
Safety
Neoplasms

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma. / Tatsugami, Katsunori; Eto, Masatoshi; Harano, Masahiko; Hamaguchi, Masumitsu; Miyamoto, Toshihiro; Morisaki, Takashi; Furue, Masutaka; Akashi, Koichi; Naito, Seiji.

In: International Journal of Urology, Vol. 15, No. 8, 01.08.2008, p. 694-698.

Research output: Contribution to journalArticle

@article{cdb8d0c7d46b435298300633c380af6e,
title = "Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma",
abstract = "Objectives: To evaluate the safety and efficacy of dendritic cell (DC) therapy in combination with interferon-α (IFN-α) in patients with advanced renal cell carcinoma. Methods: Seven patients, with progressive disease following IFN-α and interleukin (IL)-2 treatment, were treated with monocyte-derived DC (Mo-DC) and IFN-α between February 2004 and September 2006. They received Mo-DC once a week for 5 weeks and then every 2 weeks either intradermally or intratumorally. IFN-α (5-6 million U) was subcutaneously administered three times a week. Tumor size was evaluated by computed tomography scans before and after the 5th and 10th DC vaccination. A delayed-type hypersensitivity test was performed after the 4th and 5th DC administration for immunological monitoring. Results: Five patients had stable disease while the remaining two patients had progressive disease following 4 months of vaccination. In six patients the time to progression was prolonged in comparison with the previous cytokine treatment. Six patients showed delayed-type hypersensitivity after the 4th or 5th immunization. Three patients developed high fever following DC immunization. Treatment was associated with transient flu-like symptoms. Conclusions: Our data indicate that DC therapy combined with IFN-α is safe and has the potential for prolonging the time to progression in patients with advanced renal cell carcinoma.",
author = "Katsunori Tatsugami and Masatoshi Eto and Masahiko Harano and Masumitsu Hamaguchi and Toshihiro Miyamoto and Takashi Morisaki and Masutaka Furue and Koichi Akashi and Seiji Naito",
year = "2008",
month = "8",
day = "1",
doi = "10.1111/j.1442-2042.2008.02088.x",
language = "English",
volume = "15",
pages = "694--698",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Dendritic cell therapy in combination with interferon-α for the treatment of metastatic renal cell carcinoma

AU - Tatsugami, Katsunori

AU - Eto, Masatoshi

AU - Harano, Masahiko

AU - Hamaguchi, Masumitsu

AU - Miyamoto, Toshihiro

AU - Morisaki, Takashi

AU - Furue, Masutaka

AU - Akashi, Koichi

AU - Naito, Seiji

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Objectives: To evaluate the safety and efficacy of dendritic cell (DC) therapy in combination with interferon-α (IFN-α) in patients with advanced renal cell carcinoma. Methods: Seven patients, with progressive disease following IFN-α and interleukin (IL)-2 treatment, were treated with monocyte-derived DC (Mo-DC) and IFN-α between February 2004 and September 2006. They received Mo-DC once a week for 5 weeks and then every 2 weeks either intradermally or intratumorally. IFN-α (5-6 million U) was subcutaneously administered three times a week. Tumor size was evaluated by computed tomography scans before and after the 5th and 10th DC vaccination. A delayed-type hypersensitivity test was performed after the 4th and 5th DC administration for immunological monitoring. Results: Five patients had stable disease while the remaining two patients had progressive disease following 4 months of vaccination. In six patients the time to progression was prolonged in comparison with the previous cytokine treatment. Six patients showed delayed-type hypersensitivity after the 4th or 5th immunization. Three patients developed high fever following DC immunization. Treatment was associated with transient flu-like symptoms. Conclusions: Our data indicate that DC therapy combined with IFN-α is safe and has the potential for prolonging the time to progression in patients with advanced renal cell carcinoma.

AB - Objectives: To evaluate the safety and efficacy of dendritic cell (DC) therapy in combination with interferon-α (IFN-α) in patients with advanced renal cell carcinoma. Methods: Seven patients, with progressive disease following IFN-α and interleukin (IL)-2 treatment, were treated with monocyte-derived DC (Mo-DC) and IFN-α between February 2004 and September 2006. They received Mo-DC once a week for 5 weeks and then every 2 weeks either intradermally or intratumorally. IFN-α (5-6 million U) was subcutaneously administered three times a week. Tumor size was evaluated by computed tomography scans before and after the 5th and 10th DC vaccination. A delayed-type hypersensitivity test was performed after the 4th and 5th DC administration for immunological monitoring. Results: Five patients had stable disease while the remaining two patients had progressive disease following 4 months of vaccination. In six patients the time to progression was prolonged in comparison with the previous cytokine treatment. Six patients showed delayed-type hypersensitivity after the 4th or 5th immunization. Three patients developed high fever following DC immunization. Treatment was associated with transient flu-like symptoms. Conclusions: Our data indicate that DC therapy combined with IFN-α is safe and has the potential for prolonging the time to progression in patients with advanced renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=49549107094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49549107094&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2008.02088.x

DO - 10.1111/j.1442-2042.2008.02088.x

M3 - Article

C2 - 18564205

AN - SCOPUS:49549107094

VL - 15

SP - 694

EP - 698

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 8

ER -